Trial Profile
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Capecitabine; Cetuximab; Docetaxel; Fluorouracil; Methotrexate; Paclitaxel; Tegafur
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms EAGLE
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Feb 2023 Results of pooled analysis assessing the tumor mutational burden (TMB) and outcomes in the phase 2 HAWK/CONDOR (n=153) and phase 3 EAGLE (n=247) studies of durvalumab with or without tremelimumab in platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma, published in the Clinical Cancer Research.
- 12 Dec 2020 This trial is completed in Belgium, Croatia, Czech Republic, Germany and Hungary (Global End Date: 13 Nov 2020), according to European Clinical Trials Database record.
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.